World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
93
Citations
69448
World Ranking
10641
National Ranking
5472

Overview

Thomas J. Lynch is affiliated with Johns Hopkins University in the United States. Their research primarily spans the fields of Medicine and Psychology, with a focus on Clinical Psychology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine, Social Psychology, and Pediatrics, Perinatology and Child Health.

Their work covers a range of topics including Breast Cancer Treatment Studies, Suicide and Self-Harm Studies, Mental Health Treatment and Access, Counseling Practices and Supervision, Personality Disorders and Psychopathology, Psychotherapy Techniques and Applications, and Psychological Testing and Assessment.

Thomas J. Lynch has contributed to several publication venues, including UNC Libraries, Pathology, Archives of Suicide Research, Canadian Journal of Emergency Medicine, and Case Reports in Gastroenterology.

Notable recent papers include:

  • The Content of Patient-Identified Suicidal Drivers within CAMS Treatment Planning (2022, Archives of Suicide Research)
  • LO48: Pediatric cannabinoid hyperemesis syndrome in the emergency department: a 5-year retrospective review (2020, Canadian Journal of Emergency Medicine)
  • The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS) (2022, UNC Libraries)
  • Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 (2020, UNC Libraries)
  • Breast implant-associated ALCL (BIA-ALCL). Experience at Douglass Hanly Moir Pathology (2023, Pathology)

Frequent co-authors include Rhonda M. Merwin, Prudence F. Cuper, Kibby McMahon, Leonard Hsu, and Kwan Yee Tsu.

Best Publications

  • Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

    Thomas J Lynch;Daphne W Bell;Raffaella Sordella;Sarada Gurubhagavatula

  • Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer

    Jennifer S. Temel;Joseph A. Greer;Alona Muzikansky;Emily R. Gallagher

  • Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

    Eunice L. Kwak;Yung-Jue Bang;D. Ross Camidge;Alice T. Shaw

  • Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

    Lecia V. Sequist;Belinda A. Waltman;Dora Dias-Santagata;Subba Digumarthy

  • Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial

    Mark G. Kris;Ronald B. Natale;Roy S. Herbst;Thomas J. Lynch

  • Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

    Alice T. Shaw;Beow Y. Yeap;Mari Mino-Kenudson;Subba R. Digumarthy

  • Detection of Mutations in EGFR in Circulating Lung-Cancer Cells

    Shyamala Maheswaran;Lecia V. Sequist;Sunitha Nagrath;Lindsey Ulkus

  • Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

    Thomas J. Lynch;Igor Bondarenko;Alexander Luft;Piotr Serwatowski

  • Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

    Eunice L. Kwak;Raffaella Sordella;Daphne W. Bell;Nadia Godin-Heymann

  • First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

    Lecia V. Sequist;Renato G. Martins;David Spigel;Steven M. Grunberg

  • Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer

    Lecia V. Sequist;Daphne W. Bell;Thomas J. Lynch;Daniel A. Haber

  • Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials

    Daphne W. Bell;Thomas J. Lynch;Sara M. Haserlat;Patricia L. Harris

  • Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.

    Scott J. Rodig;Mari Mino-Kenudson;Sanja Dacic;Beow Y. Yeap

  • Longitudinal Perceptions of Prognosis and Goals of Therapy in Patients With Metastatic Non–Small-Cell Lung Cancer: Results of a Randomized Study of Early Palliative Care

    Jennifer S. Temel;Joseph A. Greer;Joseph A. Greer;Joseph A. Greer;Sonal Admane;Sonal Admane;Sonal Admane;Emily R. Gallagher;Emily R. Gallagher;Emily R. Gallagher

  • Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib

    David M. Jackman;Beow Y. Yeap;Lecia V. Sequist;Neal Lindeman

  • Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099

    Thomas J. Lynch;Taral Patel;Luke Dreisbach;Michael McCleod

  • Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor:Results of a Phase II Trial in Patients With Advanced Non-Small-Cell Lung Cancer

    Lecia V. Sequist;Benjamin Besse;Thomas J. Lynch;Vincent A. Miller

  • Epidermal Growth Factor Receptor Inhibitor–Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management

    Thomas J. Lynch;Ed S. Kim;Beth Eaby;Jody Garey

  • Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

    Dora Dias‐Santagata;Sara Akhavanfard;Serena S. David;Kathy Vernovsky

  • XPD and XRCC1 Genetic Polymorphisms Are Prognostic Factors in Advanced Non—Small-Cell Lung Cancer Patients Treated With Platinum Chemotherapy

    Sarada Gurubhagavatula;Geoffrey Liu;Sohee Park;Wei Zhou

Frequent Co-Authors

John C. Wain
John C. Wain Harvard University
David C. Christiani
David C. Christiani Harvard University
Geoffrey Liu
Geoffrey Liu Princess Margaret Cancer Centre
Bruce A. Chabner
Bruce A. Chabner Harvard University
Lecia V. Sequist
Lecia V. Sequist Harvard University
Bruce E. Johnson
Bruce E. Johnson Harvard University
Daniel A. Haber
Daniel A. Haber Harvard University
Pasi A. Jänne
Pasi A. Jänne Harvard University
Jennifer S. Temel
Jennifer S. Temel Harvard University
Donna Neuberg
Donna Neuberg Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens doors to several related online degrees and alternative career paths in healthcare. Many students interested in patient care consider direct entry online msn programs for those without a nursing background. These programs offer a pathway into advanced practice nursing roles efficiently, even for non-nurses.

For applicants prioritizing accessibility, there are also nursing schools with high acceptance rates, making entry into the nursing field more achievable. In addition, some institutions offer opportunities for aspiring nurses by providing nursing schools that don't require teas test as part of their admissions process, reducing obstacles for prospective students.

If you are interested in the administrative side of healthcare, consider accredited medical billing and coding programs. There are numerous accredited medical billing and coding schools online with financial aid options available, making this career path more accessible and affordable.

Best Scientists Citing Thomas J. Lynch

Trending Scientists

Recently Published Articles